

25. Colunga Biancatelli RM, Berrill M, Mohammed YH et al. Melatonin for the treatment of sepsis: the scientific rationale. *J Thorac Dis* 2020; 12 (Suppl 1):S54-S65.
26. Reiter RJ, Abreu-Gonzalez P, Marik PE et al. Therapeutic algorithm for use of melatonin in patients with COVID-19. *Front Med* 2020; 7:226.
27. Reiter RJ, Sharma R, Ma Q et al. Melatonin inhibits COVID-19-induced cytokine storm by reversing aerobic glycolysis in immune cells: A mechanistic analysis. *Medicine in Drug Discovery* 2020; 6:100044.
28. Zhang R, Wang X, Ni L et al. COVID-19: Melatonin as a potential adjuvant treatment. *Life Sci* 2020; 250:117583.
29. Kleszczynski K, Slominski AT, Steinbrink K et al. Clinical trials for use of melatonin to fight COVID-19 are urgently needed. *Nutrients* 2020; 12.
30. Coto-Montes A, Boga JA. ER stress and autophagy induced by SARS-CoV-2: The target for melatonin treatment. *Melatonin Res* 2020; 3:346-61.
31. Gandolfi JV, Di Bernardo AP, Chanes DA et al. The effects of melatonin supplementation on sleep quality and assessment of the serum melatonin in ICU patients: A randomized controlled trial. *Crit Care Med* 2020.
32. Castillo RR, Quizon GR, Juco MJ et al. Melatonin as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization (MAC-19 PRO): a case series. *Melatonin Res* 2021; 3:297-310.
33. Ramiall V, Zucker J, Tatonetti N. Melatonin is significantly associated with survival of intubated COVID-19 patients. *medRxiv* 2021.
34. Farnoosh G, Akbaariqomi M, Badri T et al. Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: A randomized, double-blind clinical trial. *medRxiv* 2021.
35. Shneider A, Kudriavtsev A, Vakhusheva A. Can melatonin reduce the severity of COVID-19 pandemic. *medRxiv* 2020.
36. O'Brien MP, Forleo-Neto E, Musser BJ et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. *N Engl J Med* 2021.
37. Freedberg DE, Conigliaro J, Sobieszczyk ME et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. *medRxiv* 2020.
38. Janowitz T, Baglenz E, Pattinson D et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalized patients: a case series. *Gut* 2020; 69:1592-97.
39. Mather JF, Seip RL, McKay RG. Impact of famotidine use on clinical outcomes of hospitalized COVID-19 patients. *Am J Gastroenterol* 2020.
40. Malone RW, Tisdall P, Fremont-Smith P et al. COVID-19: Famotidine, Histamine, Mast Cells, and mechanisms. *Research Square* 2020.
41. Sethia R, Prasad M, Mahapatra SJ et al. Efficacy of famotidine for COVID-19: A systematic review and meta-analysis. *medRxiv* 2020.
42. Shoabi A, Fortin S, Weinstein R et al. Comparative effectiveness of famotidine in hospitalized COVID-19 patients. *medRxiv* 2020.
43. Yeramaneni S, Doshi P, Sands K et al. Famotidine use is not associated with 30-day mortality: A coarsened exact match study in 7158 hospitalized COVID-19 patients from a large healthcare system. *medRxiv* 2020.
44. Almario CV, Chey WD, Spiegel BM. Increased risk of COVID-19 among users of proton pump inhibitors. *Am J Gastroenterol* 2020.
45. Lee SW, Ha EK, Moon SY et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. *Gut* 2021; 70:76-84.
46. Munoz J, Ballester MR, Antonijoan RM et al. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18 mg tablet in healthy adult volunteers. *PLoS Neglected Tropical Diseases* 2018; 12:e0006020.
47. Rattis BA, Ramos SG, Celes MR. Curcumin as a potential treatment for COVID-19. *Frontiers in Pharmacology* 2021; 21:675287.
48. Chai YS, Chen YQ, Lin SH et al. Curcumin regulates the differentiation of naive CD4+ T cells and activates IL-10 immune modulation against acute lung injury in mice. *Biomedicine and Pharmacotherapy* 2020; 125:109946.
49. Thimmulappa RK, Mudnakudu-Nagaraju KK, Shivamallu C et al. Antiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19. *Heliyon* 2021; 7:e06350.

50. Jena AB, Kanungo N, Nayak V et al. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies. *Scientific Reports* 2021; 11:2043.
51. Somi VK, Mehta A, Ratre YK et al. Curcumin, a traditional spice component, can hold promise against COVID-10? *Eur J Pharmacol* 2020; 886:173551.
52. Tahmasebi S, El-Esawi MA, Mahmoud ZH et al. Immunomodulatory effects of nanocurcumin on the Th17 cell responses in mild and severe COVID-19 patients. *J Cell Physiol* 2021; 236:5325-38.
53. Valizadeh H, Danshina S, Gencer MZ et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. *International Immunopharmacology* 2020; 89:107088.
54. Al-Hatamleh MA, Hatmal MM, Sattat K et al. Antiviral and immunomodulatory effects of phytochemicals from honey against COVID-19: Potential mechanisms of action and future directions. *Molecules* 2020; 25:5017.
55. Hashem HE. *In Silico* approach of some selected honey constituents as SARS-CoV-2 main protease (COVID-19) inhibitors. *medRxiv* 2021.
56. Ashraf S, Ashraf S, Ashraf M et al. Honey and *Nigella sativa* against COVID-19 in Pakistan (HNS-COVID-PK): A multi-center placebo-controlled randomized clinical trial. *medRxiv* 2021.
57. Salim B, Noureddine M. Identification of compounds from *Nigella Sativa* as new potential inhibitors of 2019 Novel Coronavirus (COVID-10): Molecular docking study. *ChemRxiv* 2021.
58. Fakhar-e-Alam Kulyar M, Li R, Mehmood K et al. Potential influence of *Nagella sativa* (Black cummin) in reinforcing immune system: A hope to decelerate the COVID-19 pandemic. *Phytomedicine* 2021; 85:153277.
59. Khazdair MR, Ghafari S, Sadeghi M. Possible therapeutic effects of *Nigella sativa* and its thymoquinone on COVID-19. *Pharmaceutical Biology* 2021; 59:696-703.
60. Islam MN, Hossain KS, Sarker PP et al. Revisiting pharmacological potentials of *Nigella sativa* seed: A promising option for COVID-19 prevention and cure. *Phytotherapy Research* 2021; 35:1329-44.
61. Rahman MT. Potential benefits of combination of *Nigella sativa* and Zn supplements to treat COVID-19. *J Herbal Med* 2020; 23:100382.
62. Gorial FI, Mashhadani S, Sayaly HM et al. Effectiveness of Ivermectin as add-on therapy in COVID-19 management (Pilot Trial). *medRxiv* 2020.
63. Khan MS, Khan MS, Debnath Cr et al. Ivermectin treatment may improve the prognosis of patients with COVID-19. *Archivos de Bronconeumologia* 2020.
64. Rajter JC, Sherman MS, Fattah N et al. ICON (Ivermectin in Covid Nineteen) study: Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19. *Chest* 2020.
65. Niaee MS, Gheibl N, Namdar P et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. *Research Square* 2020.
66. Elgazzar A, Hany B, Youssef SA et al. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. *Research Square* 2020.
67. Hashim HA, Maulood MF, Rasheed AM et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Bagdad, Iraq. *medRxiv* 2020.
68. Maghbooli Z, Sahraian MA, Ebrahimi M et al. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/ml reduced risk for adverse clinical outcomes in patients with COVID-19 infection. *PLoS ONE* 2020; 15:e0239799.
69. Grant WB, Lahore H, McDonnell SL et al. Evidence that Vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. *Nutrients* 2020; 12:988.
70. Kaufman HW, Niles JK, Kroll MH et al. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D level. *PLoS ONE* 2020; 15:e0239252.
71. Lau FH, Majumder R, Torabi R et al. Vitamin D insufficiency is prevalent in severe COVID-19. *medRxiv* 2020.
72. Marik PE, Kory P, Varon J. Does vitamin D status impact mortality from SARS-CoV-2 infection? *Medicine in Drug Discovery* 2020.
73. Rhodes JM, Subramanian S, Laird E et al. Editorial: Low population mortality from COVID-19 in countries south of 35 degrees North - supports vitamin D as a factor determining severity. *Alimentary Pharmacology & Therapeutics* 2020; (in press).
74. Dancer RC, Parekh D, Lax S et al. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). *Thorax* 2015; 70:617-24.

75. Llie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. *Aging Clin Exp Res* 2020.
76. Daneshkhah A, Eshein A, Subramanian H. The role of vitamin D in suppressing cytokine storm of COVID-19 patients and associated mortality. *medRxiv* 2020.
77. Bergman P, Lindh AU, Bjorkhem-Bergman L et al. Vitamin D and respiratory tract infections: A systematic review and meta-analysis of randomized controlled trials. *PLoS ONE* 2013; 8:e65835.
78. Carpagnano GE, Lecce V, Quaranta VN et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. *J Endocrinol Invest* 2020.
79. Israel A, Cicurel A, Feldhamer I et al. The link between vitamin D deficiency and Covid-19 in a large population. *medRxiv* 2020.
80. Radujkovic A, Hippchen T, Tiwari-Heckler S et al. Vitamin D deficiency and outcome of COVID-19 patients. *Nutrients* 2020; 12:2757.
81. Rizzoli R. Vitamin D supplementation: upper limit for safety revisited. *Aging Clin Exp Res* 2020.
82. Annweiler C, Hanotte B, de L'Eprevier CG et al. Vitamin D and survival in COVID-19 patients: A quasi-experimental study. *Journal of Steroid Biochemistry & Molecular Biology* 2020.
83. Moozhipurath RK, Kraft L, Skiera B. Evidence of protective role of Ultraviolet-B (UVB) radiation in reducing COVID-19 deaths. *Nature Research* 2020; 10:17705.
84. Cangiano B, Fatti LM, Danesi L et al. Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests. *Aging* 2020; 12.
85. De Smet D, De Smet K, Herroelen P et al. Serum 25(OH)D level on hospital admission associated with COVID-19 stage and mortality. *Am J Clin Pathol* 2020.
86. Cozier YC, Castro-Webb N, Hochberg NS et al. Lower serum 25(OH) D levels associated with higher risk of COVID-19 infection in U.S. black women. *PLoS ONE* 2021; 16:e0255132.
87. Murai IH, Fernandes AL, Sales LP et al. Effect of vitamin D3 supplementation vs placebo on hospital length of stay in patients with severe COVID-19: A multicenter, double-blind, randomized controlled trial. *JAMA* 2020.
88. Wu Y, Cheng X, Jiang G et al. Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization. *npj Biofilms and Microbiomes* 2021; 7:61.
89. Hazan S, Stollman N, Bozkurt H et al. The missing microbes: Bifidobacterium and Faecalibacterium depletion and loss of microbiome diversity as potential susceptibility markers for SARS-CoV-2 infection and severity. *Clinical Gastroenterology & Hepatology* 2021.
90. Din AU, Mazhar M, Waseem M et al. SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotic role. *Biomedicine & Pharmacotherapy* 2021; 133:110947.
91. Yeoh YK, Zuo T, Lui GC et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. *Gut* 2021; 70:698-706.
92. Rosa DD, Dias MM, Grzeskowiak LM et al. Milk kefir: nutritional, microbiological and health benefits. *Nutrition Research Reviews* 2017; 30:82-96.
93. Kim DH, Jeong D, Kim H et al. Modern perspectives on the health benefits of kefir in next generation sequencing era: Improvement of the host gut microbiota. *Critical Reviews in Food Science and Nutrition* 2019; 59:1782-93.
94. Maggini S, Beveridge S, Suter M. A combination of high-dose vitamin C plus zinc for the common cold. *Journal of International Medical Research* 2012; 40:28-42.
95. Colunga Biancatelli RM, Berrill M, Catravas JD et al. Quercetin and Vitamin C: experimental therapy for the prevention and treatment of SARS-CoV-2 via synergistic action. *Front Immunol* 2020.
96. Kyung Kim T, Lim HR, Byun JS. Vitamin C supplementation reduces the odds of developing a common cold in Republic of Korea Army recruits: a randomised controlled trial. *BMJ Mil Health* 2020.
97. Colunga Biancatelli RM, Berrill M, Marik PE. The antiviral properties of vitamin C. *Expert Rev Anti Infect Ther* 2020; 18:99-101.
98. Hiedra R, Lo KB, Elbashabsheh M et al. The use of IV vitamin C for patients with COVID-19: a case series. *Exp Rev Anti Infect Ther* 2020.
99. Khaerunnisa S. Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. *medRxiv* 2020.

100. Chen L, Li J, Luo C et al. Binding interaction of quercetin-3-B-galactoside and its synthetic derivatives with SARS-CoV 3CL: structure-activity relationship reveal salient pharmacophore features. *Bioorganic & Medicinal Chemistry Letters* 2006; 14:8295-306.
101. Nain Z, Rana HK, Lio P et al. Pathogenic profiling of COVID-19 and SARS-like viruses. *Briefings in Bioinformatics* 2020.
102. Yi L, Li Z, Yuan K et al. Small molecules blocking the entry of severe respiratory syndrome coronavirus into host cells. *J Virol* 2020; 78:11334-39.
103. Shakoor H, Feehan J, Dhaheri AS et al. Immune-boosting role of vitamins D,C,E, zinc, selenium and omega-3 fatty acids: could they help against COVID-19. *Maturitas* 2020.
104. Calder PC. Nutrition, immunity and COVID-19. *BMJ Nutrition, Prevention & Health* 2020; 3.
105. Abian O, Ortega-Alarcon D, Jimenez-Alesanco A et al. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. *International Journal of Biological Macromolecules* 2020; 164:1693-703.
106. Hemila H, Carr A, Chalker E. Vitamin C may increase the recovery rate of outpatient cases of SARS-CoV-2 infection by 70%: reanalysis of the COVID A to Z randomized clinical trial. *Research Square* 2021.
107. Marik PE. Hydrocortisone, Ascorbic Acid and Thiamine (HAT therapy) for the treatment of sepsis. *Focus on ascorbic acid. Nutrients* 2018; 10:1762.
108. Marik PE. Vitamin C for the treatment of sepsis: The scientific rationale. *Pharmacol Therapeut* 2018; 189:63-70.
109. Chen L, Li J, Luo C et al. Binding interaction of quercetin-3-B-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure-activity relationship studies reveal salient pharmacophore features. *Bioorganic & Medicinal Chemistry* 2020; 14:8295-306.
110. Ono K, Nakane H. Mechanisms of inhibition of various cellular DNA and RNA polymerases by several flavonoids. *J Biochem* 1990; 108:609-13.
111. Kaul TN, Middleton E, Pgra PL. Antiviral effects of flavonoids on human viruses. *J Med Virol* 1985; 15:71-79.
112. Shinozka K, Kikuchi Y, Nishino C et al. Inhibitory effect of flavonoids on DNA-dependent DNA and RNA polymerases. *Experientia* 1988; 44:882-85.
113. Martin JH, Crotty S, Warren P. Does an apple a day keep the doctor away because a phytoestrogen a day keeps the virus at bay? A review of the anti-viral properties of phytoestrogens. *Phytochemistry* 2007; 68:266-74.
114. Smith M, Smith JC. Repurposing therapeutics for COVID-19: Supercomputer-based docking to the SARS-CoV-2 viral spike protein and viral spike protein-human ACE2 interface. *ChemRxiv* 2020.
115. Leyva-Lopez N, Gutierrez-Grijalva EP, Ambriz-Perez D. Flavonoids as cytokine modulators: A possible therapy for inflammation-related diseases. *Int J Mol Sci* 2016; 17:921.
116. Nair MP, Kandaswami C, Mahajan S et al. The flavonoid, quercetin, differentially regulates Th-1 (INF) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. *Biochimica et Biophysica Acta* 2020; 1593:29-36.
117. Saeedi-Boroujeni A, Mahmoudian-Sani MR. Anti-inflammatory potential of Quercetin in COVID-19 treatment. *J Inflamm* 2021; 18:3.
118. Dabbagh-Bazarbachi H, Clergeaud G, Quesada IM et al. Zinc ionophore activity of Quercetin and Epigallocatechin-gallate: From Hepa 1-6 cells to a liposome model. *J Agric Food Chem* 2014; 62:8085-93.
119. Nieman DC, Simonson A, Sakaguchi CA et al. Acute Ingestion of a Mixed Flavonoid and Caffeine Supplement Increases Energy Expenditure and Fat Oxidation in Adult Women: A Randomized, Crossover Clinical Trial. *Nutrients* 2019; 11.
120. Nieman DC, Kay CD, Rathore AS et al. Increased Plasma Levels of Gut-Derived Phenolics Linked to Walking and Running Following Two Weeks of Flavonoid Supplementation. *Nutrients* 2018; 10.
121. Nieman DC, Ramamoorthy S, Kay CD et al. Influence of Ingesting a Flavonoid-Rich Supplement on the Metabolome and Concentration of Urine Phenolics in Overweight/Obese Women. *Journal of Proteome Research* 2017; 16:2924-35.
122. Cialdella-Kam L, Ghosh S, Meaney MP et al. Quercetin and Green Tea Extract Supplementation Downregulates Genes Related to Tissue Inflammatory Responses to a 12-Week High Fat-Diet in Mice. *Nutrients* 2017; 9.
123. Ohgitani E, Shin-Ya M, Ichitani M et al. Rapid inactivation in vitro of SARS-CoV-2 in saliva by black tea and green tea. *bioRxiv* 2021.

124. Giuliani C, Bucci I, Di Santo S et al. The flavonoid quercetin inhibits thyroid-restricted genes expression and thyroid function. *Food and Chemical Toxicology* 2014; 66:23-29.
125. de Souza dos Santos MC, Goncalves CF, Vaisman M et al. Impact of flavonoids on thyroid function. *Food and Chemical Toxicology* 2011; 49:2495-502.
126. Chandra AK, De N. Catechin induced modulation in the activities of thyroid hormone synthesizing enzymes leading to hypothyroidism. *Mol Cell Biochem* 2013; 374:37-48.
127. Pistollato F, Masias M, Agudo P et al. Effects of phytochemicals on thyroid function and their possible role in thyroid disease. *Ann N Y Acad Sci* 2019; 1433:3-9.
128. Sathyapalan T, Manuchehri AM, Thatcher NJ et al. The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: A randomized, double-blind, crossover study. *J Clin Endocrinol Metab* 2020; 96:1422-49.
129. Tonstad S, Jaceldo-Siegl K, Messina M et al. The association between soya consumption and serum thyroid-stimulating hormone in the Adventist Health Study-2. *Public Health Nutr* 2016; 19:1464-70.
130. Colombo D, Lunardon L, Bellia G. Cyclosporine and herbal supplement interactions. *Journal of Toxicology* 2014; 2014:145325.
131. Vogel-Gonzalez M, Tallo-Parra M, Herrera-Fernandez V et al. Low zinc levels at admission associates with poor clinical outcomes in SARS-CoV-2 infection. *Nutrients* 2021; 13:562.
132. te Velthuis AJ, van den Worm SH, Sims AC et al. Zn<sup>2+</sup> inhibits Coronavirus and Arterivirus RNA polymerase activity In Vitro and Zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog* 2010; 6:e1001176.
133. Gammoh NZ, Rink L. Zinc in Infection and Inflammation. *Nutrients* 2017; 9.
134. Hemila H. Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage. *J Royal Soc Med Open* 2017; 8:1-7.
135. Hoeger J, Simon TP, Beeker T et al. Persistent low serum zinc is associated with recurrent sepsis in critically ill patients - A pilot study. *PLoS ONE* 2017; 12:e0176069.
136. Willis MS, Monaghan SA, Miller ML et al. Zinc-induced copper deficiency. A report of three cases initially recognized on bone marrow examination. *Am J Clin Pathol* 2005; 123:125-31.
137. Shakoor H, Freehan J, Mikkelsen K et al. Be well: A potential role for vitamin B in COVID-19. *Maturitas* 2020.
138. dos Santos LM. Can vitamin B12 be an adjuvant to COVID-19 treatment? *GSC Biological and Pharmaceutical Sciences* 2020; 11.
139. Kandeel M, Al-Nazawi M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. *Life Sci* 2020; 251:117627.
140. Tan CW, Ho LP, Kalimuddin S et al. Cohort study to evaluate effect of vitamin D, magnesium, and vitamin b12 in combination on severe outcome progression in older patients with coronavirus (COVID-19). *Nutrition* 2020; 80:111017.
141. Zhang P, Tsuchiya K, Kinoshita T et al. Vitamin B6 prevents IL-1B protein production by inhibiting NLRP3 inflammasome activation. *J Biol Chem* 2020; 291:24517-27.
142. Hashim HA, Maulood MF, rasheed AM et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Bagdad, Iraq. *medRxiv* 2020.
143. Alam MT, Murshed R, Bhiuyan E et al. A case series of 100 COVID-19 positive patients treated with combination of Ivermectin and Doxycycline. *Bangladesh Coll Phys Surg* 2020; 38:10-15.
144. Chowdhury AT, Shahabz M, Karim MR et al. A randomized trial of ivermectin-doxycycline and hydrochloroquine-azithromycin therapy on COVID-19 patients. *Research Square* 2020.
145. Chamie J. Real-World evidence: The case of Peru, casualty between Ivermectin and COVID-19 infection fatality rate. *ResearchGate* 2020.
146. Caly L, Druce JD, Catton MG et al. The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res* 2020.
147. Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. *In Vivo* 2020; 34:3023-26.
148. Maurya DK. A combination of Ivermectin and Doxycycline possibly blocks the viral entry and modulate the innate immune response in COVID-19 patients. *ChemRxiv* 2020.
149. Yang SN, Atkinson SC, Wang C et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer. *Antiviral Res* 2020; 177:104760.

150. Dayer MR. Coronavirus (2019-nCoV) deactivation via spike glycoprotein shielding by old drugs, bioinformatic study. Preprints 2020.
151. Swargiary A. Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from silico studies. Research Square 2020.
152. Kalfas S, Visvanathan K, Chan K et al. The therapeutic potential of ivermectin for COVID-19: A systematic review of mechanisms and evidence. medRxiv 2020.
153. Chamie-Quintero JJ, Hibberd JA, Scheim DE. Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths,  $p=0.002$  for effect by state, then 13-fold increase after ivermectin use restricted. medRxiv 2021.
154. Wehbe Z, Wehbe M, Iratni R et al. Repurposing Ivermectin for COVID-19: Molecular aspects and therapeutic possibilities. Front Immunol 2021; 12:663586.
155. Hazan S, Dave S, Gunaratne AW et al. Effectiveness of ivermectin-based multidrug therapy in severe hypoxic ambulatory COVID-19 patients. medRxiv 2021.
156. Bryant A, Lawrie TA, Dowswell T et al. Ivermectin for the prevention and treatment of COVID-19 infection: a systematic review and meta-analysis. Lancet 2021.
157. Hill A, Garratt A, Levi J et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Open Forum Infectious Diseases 2021.
158. Rossignol JF, Bardin MC, Oaks JB et al. Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization. medRxiv 2021.
159. Cadegiani FA, Goren A, Wambier CG et al. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly reduced symptoms compared to known outcomes in untreated patients. New Microbes and New Infections 2021; 43:100915.
160. Elalfy H, Besheer T, El-Mesery A et al. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19. J Med Virol 2021; 93:3176-83.
161. Hong SK, Kim HJ, Song CS et al. Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice. International Immunopharmacology 2012; 13:23-27.
162. Rossignol JF. Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Res 2014; 110:94-103.
163. Padmanabhan S, Padmanabhan K. The devil is in the dosing- targeting the interferon pathway by repositioning Nitazoxanide against COVID-19. Research Square 2021.
164. Cao J, Forrest CJ, Zhang X. A screen of the NIH clinical collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Res 2015; 114:1-10.
165. Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. Journal of Infection and Public Health 2016; 9:227-30.
166. Piacentini S, La Frazia S, Riccio A et al. Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57. Scientific Reports 2018; 8:10425.
167. Merchant HA. CoViD-19: An early intervention therapeutic strategy to prevent developing a severe disease as an alternative approach to control the pandemic. medRxiv 2021.
168. da Silva JK, Figueirido PL, Byler KG et al. Essential oils as antiviral agents, potential of essential oils to treat SARS-CoV-2 infection: an In-Silico investigation. Int J Mol Sci 2020; 21:3426.
169. Seet RC, Quek AM, Ooi DS et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial. Int J Infect Dis 2021.
170. Vergara-Buenaventura A, Castro-ruiz C. Use of mouthwashes against COVID-19 in dentistry. British Journal of Oral and Maxillofacial Surgery 2020; 58:924-27.
171. Baxter AL, Schwartz KR, Johnson RW et al. Rapid initiation of nasal saline irrigation: hospitalizations in COVID-19 patients randomized to alkalization or povidone-iodine compared to a national dataset. medRxiv 2021.
172. Seneviratne CJ, Balan P, Ki KK et al. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: Randomized controlled trial in Singapore. Infection 2020; 49:305-11.
173. Frank S, Brown SM, Capriotti JA et al. In vitro efficacy of a povidone-iodine nasal antiseptic for rapid inactivation of SARS-CoV-2. JAMA Otolaryngol Head Neck Surg 2020; 146:1054-58.
174. Burton MJ, Clarkson JE, Goulao B et al. Antimicrobial mouthwashes (gargling) and nasal sprays to protect healthcare workers when undertaking aerosol-generating procedures (AGPs) on patients without suspected or confirmed COVID-19 infection (Review). Cochrane Database of Syst Rev 2020; 9:CD013628.

175. Meister TL, Briggemann Y, Todt D et al. Virucidal efficacy of different oral rinses against severe acute respiratory syndrome coronavirus 2. *J Infect Dis* 2020; 222:1289-92.
176. Shiraishi T, Nakagawa Y. Evaluation of the bactericidal activity of povidone-iodine and commercially available gargle preparations. *Dermatology* 2002; 204 (suppl 1):37-41.
177. Teng F, He T, Huang S et al. Cetylpyridinium chloride mouth rinses alleviate experimental gingivitis by inhibiting dental plaque maturation. *Journal of Oral Science* 2016; 8:182-90.
178. Rosing CK, Cavagni J, Gaio EJ et al. Efficacy of two mouthwashes with cetylpyridinium chloride: a controlled randomized clinical trial. *Braz Oral res* 2017; 31:e47.
179. Green A, Roberts G, Tobery T et al. In vitro assessment of the virucidal activity of four mouthwashes containing Cetylpyridinium Chloride, ethanol, zinc and a mix of enzymes and proteins against human coronavirus. *bioRxiv* 2021.
180. Choudhury IM, Shabnam N, Ahsan T et al. Effect of 1% povidone iodine mouthwash/gargle, nasal and eye drop in COVID-19 patient. *Bioresearch Communications* 2021; 7.
181. Ader AW, Paul TL, Reinhardt W et al. Effect of mouth rinsing with two polyvinylpyrrolidone-iodine mixtures on iodine absorption and thyroid function. *J Clin Endocrinol Metab* 2021; 66:632-35.
182. Bianconi V, Violi F, Fallarino F et al. Is acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19? *Drugs* 2020.
183. Muller C, Karl N, Ziebuhr J et al. D,L-lysine acetylsalicylate + glycine impairs coronavirus replication. *J Antivir Antiretrovir* 2020.
184. Draghici S, Nguyen TM, Sonna LA et al. COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases. *Bioinformatics* 2020.
185. Varatharajah N. COVID-19 CLOT: What is it? Why in the lungs? Extracellular histone, "auto-activation" of prothrombin, emperipolesis, megakaryocytes, "self-association" of Von Willebrand factor and beyond. *Preprints* 2020.
186. Cloutier N, Allaeyts I, Marcoux G et al. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. *PNAS* 2018;E1550-E1559.
187. Hottz ED, Azevedo-Quintanilha Ig, Palhinha L et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. *Blood* 2020; 136:1330-1341.
188. Early high-dose vitamin D3 for critically ill, vitamin D-deficient patients. *N Engl J Med* 2019; 381:2529-40.
189. Amrein K, Martucci G, McNALLY JD. When not to use meta-analysis: Analysing the meta-analysis on vitamin D in critical care. *Clin Nutr* 2017; 36:1729-30.
190. Luks AM, Swenson ER. Pulse oximetry for monitoring patients with COVID-19 at home: Potential pitfalls and practical guidance. *Ann Thorac Med* 2020.
191. Jouffroy R, Jost D, Prunet B. Prehospital pulse oximetry: a red flag for early detection of silent hypoxemia in COVID-19 patients. *Crit Care* 2020; 24:313.
192. Lucas JM, Heinlein C, Kim T et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. *Cancer Discov* 2020; 4:1310-1325.
193. Marik PE, DePerrior SE, Ahmad Q et al. Gender-based disparities in COVID-19 patient outcomes. *Journal of Investigative Medicine* 2021; 69:814-18.
194. Liadet L, Szabo C. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease. *Crit Care* 2020; 24:318.
195. Kotfis K, Lechowicz K, Drozdal S et al. COVID-19-The potential beneficial therapeutic effects of spironolactone during SARS-CoV-2 infection. *Pharmaceuticals* 2021; 14:71.
196. Cadegiani FA, Wambier CG, Goren A. Spironolactone: An anti-androgenic and anti-hypertensive drug that may provide protection against the novel Coronavirus (SARS-CoV-2) induced acute respiratory distress syndrome (ARDS) in COVID-19. *Frontiers in Medicine* 2020; 7:453.
197. Cadegiani FA, Goren A, Wambier CG. Spironolactone may provide protection from SARA-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). *Medical Hypotheses* 2020; 143:110112.
198. Cadegiani FA, McCoy J, Zimmerman A et al. Efficacy of proxalutamide in hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled, parallel-design clinical trial. *medRxiv* 2021.
199. Wambier CG, de Pina Almeida Prado Junior B, Pereira CS et al. Brazilian blood donation eligibility criteria for dermatologic patients. *An Bras Dermatol* 2021; 87:590-595.

200. Zarehoseinzade E, Allami A, Ahmadi M et al. Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial. *Medical Journal of the Islamic Republic of Iran* 2021; 35:30.
201. Samuel RM, Majd H, Richter MN et al. Androgen signaling regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men. *Cell Stem Cell* 2020; 27:876-89.
202. Cadebiani FA, McCoy J, Wambier CG et al. Early antiandrogen therapy with dutasteride reduces viral shedding, inflammatory responses, and time-to remission in males with COVID-19: A randomized, double-blind, placebo-controlled interventional trial (EAT-DUTA AndroCoV Trial- Biochemical). *Cureus* 2021.
203. McCoy J, Goren A, Cadebiani FA et al. Proxalutamide reduces the rates of hospitalization for COVID-19 male outpatients: A randomized double-blinded placebo-controlled trial. *Front Med* 2021; 8:668698.
204. Wambier CG, Lin EM, Cadebiani FA et al. Accelerated viral clearance and symptom resolution in symptomatic COVID-19 outpatients treated with antiandrogens. *medRxiv* 2021.
205. Cadebiani FA, Goren A, Wambier CG et al. An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The PreAndroCoV Female trial. *medRxiv* 2021.
206. McCoy J, Cadebiani FA, Wambier CG et al. 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenic alopecia. *JEADV* 2021; 35:e243-e246.
207. Goren A, Wambier CG, Herrera S et al. Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort of 77 hospitalized men. *JEADV* 2021; 35:e13-e15.
208. van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss (Review). *Cochrane Database of Syst Rev* 2016; 5:CD007628.
209. Seale LR, Eglini AN, McMichael AJ. Side effects related to 5 alpha-reductase inhibitor treatment of hair loss in women: A review. *J Drugs Dermatol* 2016; 15:414-19.
210. Lenze EJ, Mattar C, Zorumski CF et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19. A randomized clinical trial. *JAMA* 2020.
211. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of COVID-19. *Open Forum Infectious Diseases* 2021.
212. Hamed MG, Hagaga RS. The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients. *Medical Hypotheses* 2020; 144:110140.
213. Hoertel N, Sanchez-Rico M, Vernet R et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. *Molecular Psychiatry* 2021.
214. Zimering MB, Razzaki T, Tsang T et al. Inverse association between serotonin 2A receptor antagonist medication use and mortality in severe COVID-19 infection. *Endocrinol Diabetes Metab J* 2020; 4:1-5.
215. Sukhatme VP, Reiersen AM, Vayttaden SJ et al. Fluvoxamine: A review of its mechanism of action and its role in COVID-19. *Frontiers in Pharmacology* 2021; 12:652688.
216. Hartter S, Wang X, Weigmann H et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. *J Clin Psychopharmacology* 2021; 21:167-74.
217. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. *Thromb Haemost* 2004; 91:119-28.
218. Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D et al. Decreased serotonin content and reduced agonist-induced aggregation in platelets of chronically medicated with SSRI drugs. *Journal of Affective Disorders* 2012; 136:99-103.
219. Javors MA, Houston JP, Tekell JL et al. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. *International Journal of Neuropsychopharmacology* 2000; 3:229-35.
220. Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. *Eur J Pharmacol* 2014; 727:167-73.
221. Weinreich DM, Sivapalasingam S, Norton T et al. REGEN-CoV antibody cocktail clinical outcomes study in Covid-19 outpatients. *medRxiv* 2021.
222. Gutierrez S, Svahn SL, Johansson ME. Effects of omega-3 fatty acids on immune cells. *Int J Mol Sci* 2019; 20:5028.
223. Titos E, Rius B, Gonzalez-Periz A et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. *J Immunol* 2021; 187:5408-18.



224. Yoshihara T, Shimada K, Fukao K et al. Omega 3 polyunsaturated fatty acids suppress the development of aortic aneurysms through the inhibition of macrophage-mediated inflammation. *Circ J* 2015; 79:1470-1478.
225. Hammock BD, Wang W, Gilligan MM et al. Eicosanoids. The overlooked storm in Coronavirus Disease 2019 (COVID-19)? *Am J Pathol* 2020.
226. Das UN. Can bioactive lipids inactivate coronavirus (COVID-19)? *Arch Med Res* 2020; 51:282-86.
227. Lee CR, Zeldin DC. Resolvin infectious inflammation by targeting the host response. *N Engl J Med* 2015; 373:2183-85.
228. Serhan CN. Novel pro-resolving lipid mediators in inflammation are leads for resolution physiology. *Nature* 2014; 510:92-101.
229. Law HK, Cheng CY, Ng HY et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. *Blood* 2005; 105:2366-74.
230. Baranova A, Cao H, Zhang F. Unraveling risk genes of COVID-19 by multi-omics integrative analysis. *Frontiers in Medicine* 2021.
231. Li S, Jiang L, Li X et al. Clinical and pathological investigation of patients with severe COVID-19. *JCI Insight* 2020; 5:e138070.
232. Yang B, Fulcher JA, Ahn J et al. Clinical characteristics and outcomes of COVID-19 patients receiving compassionate use Leronlimab. *Clin Infect Dis* 2021.
233. Patterson BK, seethamraju H, Dhody K et al. Disruption of the CCL5/RANTES-CCR5 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-19. *medRxiv* 2020.
234. Patterson BK, seethamraju H, Dhody K et al. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. *International Journal of Infectious Diseases* 2021; 103:25-32.
235. Gulick RM, Fatkenheuer G, Burnside R et al. Five-year safety evaluation of Maraviroc in HIV-1-infected treatment-experienced patients. *J Acquir Immune Defic Syndr* 2014; 65:78-81.
236. Ayoub A, Alston S, Goodrich J et al. Hepatic safety and tolerability in the maraviroc clinical development program. *AIDS* 2010; 24:2743-55.
237. Giaquinto C, Mawela MP, Chokephaibutkit K et al. Pharmacokinetics, safety and efficacy of Maraviroc in treatment-experienced pediatric patients infected with CCR5=tropic HIV-1. *Pediatr Infect Dis* 2018; 37:459-65.
238. Idelsis Esquivel-Moynelo I, Perez-Escribano J, Duncan-Roberts Y et al. Effect of combination of interferon alpha-2b and interferon-gamma or interferon alpha 2b alone for elimination of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial. *medRxiv* 2020.
239. Davoudi-Monfarad E, Rahmani H, Khalili H et al. Efficacy and safety of interferon B-1a in treatment of severe COVID-19: A randomized clinical trial. *medRxiv* 2020.
240. Wang N, Zhan Y, Zhu L et al. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. *Cell Host & Microbe* 2020;ePub.
241. Meng Z, Wang T, Chen L et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent COVID-19 in medical staff in an epidemic area. *medRxiv* 2020.
242. Feld JJ, Kandel C, Biondi MJ et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. *Lancet Resp Med* 2021.
243. Berg K, Bolt G, Andersen H et al. Zinc potentiates the antiviral action of human IFN-alpha tenfold. *J Interferon Cytokine Res* 2001; 21:471-74.
244. Cakman I, Kirchner H, Rink L. Zinc supplementation reconstitutes the production of interferon-alpha by leukocytes from elderly persons. *J Interferon Cytokine Res* 1997; 17:469-72.
245. Puskarich MA, Ingraham NE, Merck LH et al. Effect of losartan on hospitalized patients with COVID-19-induced lung injury: A randomized clinical trial. *medRxiv* 2021.
246. Duarte M, Pelorosso F, Nicolosi L et al. Telmisartan for treatment of COVID-19 patients: an open multicenter randomized clinical trial. *EclinicalMedicine* 2021; 37:100962.
247. Yu LM, Bafadhel M, Doeward J et al. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. *Lancet* 2021; 398:843-55.
248. Ramakrishnan S, Nicolau DV, Langford B et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. *Lancet Resp Med* 2021.
249. Schultze A, Walker AJ, MacKenna B et al. Inhaled corticosteroids use and the risk of COVID-19 related death among 966,461 patients with COPD or asthma: An OpenSAFELY analysis. *medRxiv* 2020.

250. Aveyard P, Gao M, Lindson N et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. *Lancet Resp Med* 2021.
251. Tardif JC, Bouabdallaoui N, L'Allier PL et al. Efficacy of colchicine in non-hospitalized patients with COVID-19. *Lancet Resp Med* 2021.
252. Finkelstein Y, Aks SE, Hutson JR et al. Colchicine poisoning: the dark side of an ancient drug. *Clinical Toxicology* 2010; 48:407-14.
253. Effect of Dexamethasone in hospitalized patients with COVID-19-Preliminary report. *N Engl J Med* 2020.
254. Risch HA. Early outpatient treatment of symptomatic, High-Risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis. *Am J Epidemiol* 2020; 189:1218-26.
255. Borba MG, Val FF, Sampaio S. Effect of High vs Low Doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A randomized clinical trial. *JAMA Network Open* 2020.
256. Boulware DR, Pullen MF, Bangdiwala AS et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. *N Engl J Med* 2020.
257. Barnabas RV, Brown ER, Bershteyn A et al. Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection. *Ann Intern Med* 2020.
258. Mitja O, Corbacho-Monne M, Ubals M et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: A randomized-controlled trial. *Clin Infect Dis* 2020.
259. Mitja O, Ubals M, Corbacho-Monne M et al. A cluster-randomized trial of hydroxychloroquine as prevention of Covid-19 transmission and disease. *N Engl J Med* 2020.
260. Cavalcanti AB, Zampieri FG, Rosa RG et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. *N Engl J Med* 2020; 383:2041-52.
261. Skipper CP, Pastick KA, Engen NW. Hydroxychloroquine in nonhospitalized adults with early COVID-19. *Ann Intern Med* 2020; 173:623-31.
262. Rosenberg ES, Dufort EM, Udo T et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. *JAMA* 2020; 323:2493-502.
263. Geleris J, Sun Y, Platt J et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. *N Engl J Med* 2020.
264. Magagnoli J, Narendran S, Pereira F. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. *medRxiv* 2020.
265. Lopez A, Duclos G, Pastene B et al. Effects of hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results. *Int J Antimicrob Agents* 2020.
266. Mahevas M, Tran VT, Roumier M et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial. *medRxiv* 2020.
267. Elsayah HK, Elsayah MA, Elrazzaz MG et al. Hydroxychloroquine for treatment of non-severe COVID-19 patients: systematic review and meta-analysis of controlled clinical trials. *medRxiv* 2020.
268. Axfors C, Schmitt AM, Janiaud P et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials. *medRxiv* 2020.
269. Sbidian E, Josse J, Lemaitre G et al. Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France. *medrx* 2020.
270. Effect of hydroxychloroquine in hospitalized patients with COVID-19. *N Engl J Med* 2020; 383:2030-2040.
271. Abd-El Salam S, Esmail ES, Khalaf M et al. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. *Am J Trop Med Hyg* 2020; 103:1635-39.
272. Rajasingham R, Bangdiwala AS, Nicol MR et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. *medRxiv* 2020.
273. Self WE, Semler MW, Leither LM et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19. a randomized clinical trial. *JAMA* 2020.
274. Johnston C, Brown ER, Stewart J et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. *EClinicalMedicine* 2021.
275. Reis G, Silva EA, Silva DC et al. Effect of early treatment with hydroxychloroquine or Lopinavir and Ritonavir on risk of hospitalization among patients with COVID-19. The TOGETHER randomized clinical trial. *JAMA Network Open* 2021; 4:e216468.

276. Dubee V, Roy PM, Vielle B et al. Hydroxychloroquine in mild-to moderate COVID-19: a placebo-controlled double blind trial. *Clinical Microbiology and Infection* 2021.
277. Tett SE, Cutler DJ, Day RO et al. Bioavailability of hydroxychloroquine tablets in healthy volunteers. *Br J Clin Pharmacol* 1989; 27:771-79.
278. MacGowan A, Hamilton F, Bayliss M et al. Hydroxychloroquine serum concentrations in non-critical care patients infected with SARS-CoV-2. medRxiv 2020.
279. Nicol MR, Joshi A, Rizk ML et al. Pharmacokinetic and pharmacological properties of chloroquine and hydroxychloroquine in the context of COVID-19 infection. medRxiv 2020.
280. Scudellari M. How the coronavirus infects our cells. *Nature* 2021; 595:640-644.
281. Gautret P, Lagier JC, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents* 2020.
282. Lagier JC, Million M, Gautret P et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. *Travel Medicine and Infectious Disease* 2020.
283. Million M, Gautret P, Colson P et al. Clinical efficacy of chloroquine derivatives in COVID-19 infection: Comparative meta-analysis between big data and the real world. *New Microbes and New Infections* 2020.
284. Morgan A, Stevens J. Does *Bacopa monnieri* improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. *J Altern Complement Med* 2010; 16:753-59.
285. Azithromycin in hospitalized patients with COVID-19 (RECOVERY) a randomised, controlled, open-label, platform trial. medRxiv 2020.
286. Rosenthal N, Zhun Cao Z, Gundrum J et al. Risk factors associated with in-hospital mortality in a US National Sample of patients with COVID-19. *JAMA Network Open* 2020; 3:e2029058.
287. Butler CC, Yu LM, Dorward J et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet Resp Med* 2021.
288. Zhang X, Song Y, Ci X et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. *Inflamm Res* 2008; 57:524-29.
289. Ci X, Li H, Yu Q et al. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen activated protein kinase pathway. *Fundamental & Clinical Pharmacology* 2009; 23:449-55.
290. DiNicolantonio JJ, Barroso-Arranda J, McCarty M. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. *Open Heart* 2020; 7:e001350.
291. DiNicolantonio JJ, Barroso-Aranda J, McCarty MF. Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors. *Open Heart* 2021; 8:e001655.
292. Blum VF, Cimerman S, Huneter JR et al. Nitazoxanide superiority to placebo to treat moderate COVID-19 - A pilot prove of concept randomized double-blind clinical trial. *EClinicalMedicine* 2021; 37:100981.
293. Villar J, Confalonieri M, Pastores SM et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome (ARDS) caused by COVID-19. *Crit Care Expl* 2020; 2:e0111.
294. Fadel R, Morrison AR, Vahia A et al. Early course corticosteroids in hospitalized patients with COVID-19. *Clin Infect Dis* 2020; 71:2114-20.
295. Chroboczek T, Lacoste M, Wackenheim C et al. Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis. medRxiv 2020.
296. Wu C, Chen X, Cai Y et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan,China. *JAMA Intern Med* 2020.
297. Cruz AF, Ruiz-Antoran B, Gomez AM et al. Impact of glucocorticoid treatment in SARS-CoV-2 infection mortality: A retrospective controlled cohort study. medRxiv 2020.
298. Liu J, Zheng X, Huang Y et al. Successful use of methylprednisolone for treating severe COVID-19. *J Allergy Clin Immunol* 2020.
299. Meduri GU, Bridges L, Shih MC et al. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature. *Intensive Care Med* 2016; 42:829-40.
300. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. A meta-analysis. *JAMA* 2020.

301. Ruiz-Irastorza G, Pijoan JI, Bereciatua E et al. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. medRxiv 2020.
302. Tomazini BM, Maia IS, Cavalcanti AB et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. The CoDEX randomized clinical trial. JAMA 2020; 324:1307-16.
303. Edalatifard M, Akhtari M, Salehi M et al. Intravenous methylprednisolone pulse as a treatment for hospitalized severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J 2020.
304. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020.
305. Dequin PF, Heming N, Meziani F et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19. A randomized Clinical trial. JAMA 2020.
306. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 2021; 389:790-802.
307. Castillo ME, Costa LM, Barrios JM et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol 2020; 203:105751.
308. Elamir YM, Amir H, Lim S et al. A randomized pilot study using calcitriol in hospitalized patients. Bone 2021.
309. Loucera C, Pena-Chilet M, Esteban-Medina M et al. Real world evidence of calcifediol use and mortality rate of COVID-19 hospitalized in a large cohort of 16,401 Adalusian patients. medRxiv 2021.
310. Heaney RP, Armas LA, Shary JR et al. 25-hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr 2008; 87:1738-42.
311. Barrett TJ, Lee AH, Xia Y et al. Platelet and vascular biomarkers associate with thrombosis and death in coronavirus disease. Circulation Research 2020; 127:945-47.
312. Zhang S, Liu Y, Wang X et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. Journal of hematology & oncology 2020; 13:120.
313. Kauerova S, Bartuskova H, Muffova B et al. Statins directly influence the polarization of adipose tissue macrophages: A role in chronic inflammation. Biomedicines 2021; 9:211.
314. van der Meij E, Koning GG, Vriens PW et al. A clinical evaluation of statin pleiotrophy: Statins selectively and dose-dependently reduce vascular inflammation. PloS ONE 2013; 8:e53882.
315. Calfee CS, Delucchi KL, Sinha P et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Resp Med 2018; 6:691-98.
316. Zhang XJ, Qin JJ, Cheng X et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metabolism 2020.
317. Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA et al. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care 2020; 24:429.
318. Gupta A, Madhavan MV, Poterucha TJ et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Research Square 2020.
319. Kow CS, Hasan SS. Meta-analysis of effectiveness of statins in patients with severe COVID-19. Am J Cardiol 2020.
320. Tan WY, Young BE, Lye DC et al. Statin use is associated with lower disease severity in COVID-19 infection. Nature Research 2020.
321. Spinelli FR, Conti F, Gadina M. HiJAKing SARS-COV-2? The potential role of JAK inhibitors in the management of COVID-19. Sci Immunol 2020; 5:eabc5367.
322. Chen CX, Wang JJ, Li H et al. JAK-inhibitors for coronavirus disease-2019 (COVID): a meta-analysis. Leukemia 2021.
323. Calabrese LH, Calabrese C. Baricitinib and dexamethasone for hospitalized patients with COVID-19. Cleve Clin J Med 2021.
324. Jalali F, Rezaie S, Rola P et al. COVID-19 pathophysiology: Are platelets and serotonin hiding in plain sight? SSRN 2021.
325. Lin OA, Karim ZA, Vemana HP et al. The antidepressant 5-HT2a receptor antagonists Pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. PloS ONE 2014; 9:e87026.

326. Zaid Y, Guessous F, Puhm F et al. Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19. *Blood Advances* 2021; 5:635-39.
327. Zaid Y, Puhm F, Allaey I et al. Platelets can associate with SARS-CoV-2 RNA and are hyperactivated in COVID-19. *Circ Res* 2020; 127:1404-18.
328. Dawson C, Christensen CW, Rickaby DA et al. Lung damage and pulmonary uptake of serotonin in intact dogs. *J Appl Physiol* 1985; 58:1761-66.
329. MacLean MR, Herve P, Eddahibi S et al. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and the relevance to pulmonary arterial hypertension. *Br J Pharmacol* 2000; 131:161-68.
330. Blackshear JL, Orlandi C, Hollenberg NK. Constrictive effect of serotonin on visible renal arteries: a pharmacoangiographic study in anesthetized dogs. *J Cardiovasc Pharmacol* 1991; 17:68-73.
331. Watchorn J, Hang DY, Joslin J et al. Critically ill COVID-19 patients with acute kidney injury have reduced renal blood flow and perfusion despite preserved cardiac function: A case-control study using contrast enhanced ultrasound. *Lancet Resp Med* 2021.
332. McGoon MD, Vanhoutte PM. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. *J Clin Invest* 1984; 74:823-33.
333. Almqvist P, Skudder P, Kuenzig M et al. Effect of cyproheptadine on endotoxin-induced pulmonary platelet trapping. *Am Surg* 1984; 50:503-5.
334. Skurikhin EG, Andreeva TV, Khnelevskaya ES et al. Effect of antiserotonin drug on the development of lung fibrosis and blood system reactions after intratracheal administration of bleomycin. *Bull Exp Biol Med* 2012; 152:519-23.
335. Doaei S, Gholami S, Rastgoo S et al. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial. *J Transl Med* 2021; 19:128.
336. Wang Y, Zhang D, Du G et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicenter trial. *Lancet* 2020; 395:1569-78.
337. Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the treatment of Covid-19-Preliminary report. *N Engl J Med* 2020;ePub.
338. Spinner CD, Gottlieb RL, Criner GJ et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. A randomized clinical trial. *JAMA* 2020.
339. Pan H, Peto R, Karim QA et al. Repurposed antiviral drugs for COVID-19 - interim WHO SOLIDARITY trial. *medrx* 2020.
340. Ohl ME, Miller DR, Lund BC et al. Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19. *JAMA Network Open* 2021; 4:e2114741.
341. Ader F, Hites M, Poissy J et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. *Lancet Infect Dis* 2021.
342. Jeffreys L, Pennington SH, Duggan J et al. Remdesivir-Ivermectin combination displays synergistic interactions with improved in vitro antiviral activity against SARS-CoV-2. *bioRxiv* 2020.
343. Marik PE, Kory P, Varon J et al. MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale. *Exp Rev Anti Infect Ther* 2020.
344. Kory P, Meduri GU, Iglesias J et al. Clinical and scientific rationale for the "MATH+" hospital treatment protocol for COVID-19. *J Intensive Care Med* 2020.
345. Ranjbar K, Shahriarad R, erfani A et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalized COVID-19 patients: A triple-blinded randomized controlled trial. *BMC Infect Dis* 2021; 21:337.
346. Ko JJ, Wu C, Mehta N et al. A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19. *medRxiv* 2021.
347. Fowler AA, Truwit JD, Hite D et al. Vitamin C Infusion for Treatment In Sepsis-Induced Acute Lung Injury-CITRIS-ALI: A Randomized, Placebo Controlled Clinical Trial. *JAMA* 2018; 322:1261-70.
348. Marik PE, Khangoora V, Rivera R et al. Hydrocortisone, Vitamin C and Thiamine for the treatment of severe sepsis and septic shock: A retrospective before-after study. *Chest* 2017; 151:1229-38.
349. Barabutis N, Khangoora V, Marik PE et al. Hydrocortisone and Ascorbic Acid synergistically protect and repair lipopolysaccharide-induced pulmonary endothelial barrier dysfunction. *Chest* 2017; 152:954-62.
350. Cheng RZ. Can early and high-dose vitamin C prevent and treat coronavirus disease 2019 (COVID-19). *Medicine in Drug Discovery* 2020.

351. Wang Y, Lin H, Lin BW et al. Effects of different ascorbic acid doses on the mortality of critically ill patients: a meta-analysis. *Ann Intensive Care* 2019; 9:58.
352. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. *PharmaNutrition* 2020; 12:100190.
353. Iglesias J, Vassallo AV, Patel V et al. Outcomes of metabolic resuscitation using ascorbic acid, thiamine, and glucocorticoids in the early treatment of sepsis. *Chest* 2020; 158:164-73.
354. de Melo AF, Homem-de-Mello M. High-dose intravenous vitamin C may help in cytokine storm in severe SARS-CoV-2 infection. *Crit Care* 2020; 24:500.
355. Zhang J, Rao X, Li Y et al. High-dose vitamin C infusion for the treatment of critically ill COVID-19. *Research Square* 2020.
356. Kumari P, Dembra S, Dembra P et al. The role of vitamin C as adjuvant therapy in COVID-19. *Cureus* 2020; 12:e11779.
357. Al Sulaiman K, Al Juhani O, Badreldin HA et al. Adjunctive therapy with ascorbic in critically ill patients with COVID-19: A multicenter propensity score matched study. *Crit Care* 2021.
358. Lankadeva YR, Peiris RM, Okazaki N et al. Reversal of the pathophysiological responses to Gram-negative sepsis by megadose Vitamin C. *Crit Care Med* 2020.
359. Zhang J, Rao X, Li Y et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. *Ann Intensive Care* 2020.
360. Lavinio A, Ercole A, Battaglini D et al. Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units. *Crit Care* 2021; 25:155.
361. Patterson G, Isales CM, Fulzele S. Low level of vitamin C and dysregulation of vitamin C transporter might be involved in the severity of COVID-19 infection. *Aging and Disease* 2020; 12.
362. Tomassa-Irriguible TM, Lielsa-Berrocal L. COVID-19: Up to 87% critically ill patients had low vitamin C values. *Research Square* 2020.
363. Arvinte C, Singh M, Marik PE. Serum levels of vitamin C and vitamin D in a cohort of critically ill COVID-19 patients of a North American Community Hospital Intensive Care Unit in May 2020. A pilot study. *Medicine in Drug Discovery* 2020; 8:100064.
364. Lopes RD, Furtado RH, Bronhara B et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. *Lancet* 2021; 397:2253-63.
365. Murshed MR, Bhiyuan E, Saber S et al. A case series of 100 COVID-19 positive patients treated with combination of Ivermectin and Doxycycline. *Bangladesh Coll Phys Surg* 2020; 38:10-15.
366. Jans DA, Wagstaff KM. Ivermectin as a broad-spectrum host directed anti-viral: The real deal. *Cells* 2020; 9:2100.
367. Sharun K, Dhama K, Patel SK et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. *Ann Clin Microbiol Antimicrob* 2020; 19:23.
368. Peralta EG, Fimia-Duarte R, Cardenas JW et al. Ivermectin, a drug to be considered for the prevention and treatment of SARS-CoV-2. *Brief literature review. EC Veterinary Science* 2020; 5:25-29.
369. Al-Jassim KB, Jawad AA, Al-Masoudi EA et al. Histopathological and biochemical effects of ivermectin on kidney functions, lung and the ameliorative effects of vitamin C in rabbits. *Bas J Vet Res* 2016; 14:110-124.
370. Mudatsir M, Yufika A, Nainu F et al. Antiviral activity of ivermectin against SARS-CoV-2: an old-fashioned dog with a new trick- Literature review. *Sci Pharm* 2020; 88:36.
371. Carvallo H, Hirsch R, Farinella ME. Safety and efficacy of the combined use of Ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. *medRxiv* 2020.
372. Menezes RR, Godin AM, Rodrigues FF et al. Thiamine and riboflavin inhibit production of cytokines and increase the anti-inflammatory activity of a corticosteroid in a chronic model of inflammation induced by complete Freund's adjuvant. *Pharmacological Reports* 2020; 69:1036-43.
373. Vatsalya V, Li F, Frimodig J et al. Therapeutic prospects for Th-17 cell immune storm syndrome and neurological symptoms in COVID-19: Thiamine efficacy and safety, In-vitro evidence and pharmacokinetic profile. *medRxiv* 2020.
374. Mallat J, Lemyze M, Thevenin D. Do not forget to give thiamine to your septic shock patient! *J Thorac Dis* 2016; 8:1062-66.
375. Moskowitz A, Donnino MW. Thiamine (vitamin B1) in septic shock: a targeted therapy. *J Thorac Dis* 2020; 12 (suppl 1):S78-S83.

376. Woolum JA, Abner EL, Kelly A et al. Effect of thiamine administration on lactate clearance and mortality in patients with septic shock. *Crit Care Med* 2018; 46:1747-52.
377. Marik PE. Thiamine: An essential component of the metabolic resuscitation protocol. *Crit Care Med* 2018; 46:1869-70.
378. Al Sulaiman K, Aljuhani O, Al Dossari M et al. Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: A multicenter propensity score matched study. *Research Square* 2021.
379. Chen L, Jiang X, Huang L et al. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: A randomized sequence, open-label, two-way crossover study. *Clinical Therapeutics* 2009; 31:2242-48.
380. Lee CY, Jan WC, Tsai PS et al. Magnesium sulfate mitigates acute lung injury in endotoxemia rats. *J Trauma* 2011; 70:1177-85.
381. Salem M, Kasinski N, Munoz R et al. Progressive magnesium deficiency increases mortality from endotoxin challenge: Protective effects of acute magnesium replacement therapy [abstract]. *Crit Care Med* 1995;A260.
382. Jiang P. Does hypomagnesemia impact on the outcome of patients admitted to the intensive care unit? A systematic review and meta-analysis. *Shock* 2019; 47:288-95.
383. Rothlin RP, Vetulli HM, Duarte M et al. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. *Drug Dev Res* 2020; 81:768-70.
384. Nejat R, Sadr AS, Freitas BT et al. Losartan inhibits SARS-CoV-2 replication in vitro. *J Pharm Pharm Sci* 2021; 24:390-399.
385. Patterson BK, Guevara-Coto J, Yogendra R et al. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. *Front Immunol* 2021.
386. Oldenburg CE, Doan T. Azithromycin for severe COVID-19. *Lancet* 2020.
387. Futado RH, Berwanger O, Fonseca HA et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised trial. *Lancet* 2020.
388. Agarwal A, Mukherjee A, Kumar G et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). *BMJ* 2020; 371:m3939.
389. Simonovich VA, Pratz LD, Scibona P et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. *N Engl J Med* 2020.
390. Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E et al. Convalescent plasma for COVID-19: A multicenter, randomized clinical trial. *medRxiv* 2020.
391. Balcells ME, Rojas L, Le Corre N et al. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. *PLOS Med* 2021; 18:e1003415.
392. Janiaud P, Axfors C, Schmitt AM et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19. A systematic review and meta-analysis. *JAMA* 2021.
393. Li L, Zhang W, Hu Y et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. A randomized clinical trial. *JAMA* 2020; 324:460-470.
394. Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? *Filaria Jurnal* 2003; 3 (Suppl I):S8.
395. Thompson MA, Henderson JP, Shah PK et al. Convalescent plasma and improved survival in patients with hematologic malignancies and COVID-19. *medRxiv* 2021.
396. Rosas IO, Brau N, Waters M et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. *medRxiv* 2020.
397. Hermine O, Mariette X, Tharaux PL et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized Clinical Trial. *JAMA Intern Med* 2020.
398. Stone JH, Frigault MJ, Sterling-Boyd NJ et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. *N Engl J Med* 2020.
399. Salvarani C, Dolci G, Massari M et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. *JAMA Intern Med* 2020.
400. Salama C, Han J, Yau L et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. *N Engl J Med* 2020.
401. Gordon AC, Mouncey PR, Rowan KM et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19 - Preliminary report. *medRxiv* 2021.

402. Bassetti M, Kollef MH, Timsit JF. Bacterial and fungal superinfections in critically ill patients with COVID-19. *Intensive Care Med* 2020.
403. Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. *Clinical Microbiology & Infection* 2021; 27:9-11.
404. Le Balc'h P, Pinceaux K, Pronier C et al. Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients. *Crit Care* 2020; 24:530.
405. Koehler P, Bassetti M, Chen SC et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. *Lancet Infect Dis* 2021.
406. Xu Q, Wang T, Quin X et al. Early awake prone position combined with high-flow nasal oxygen therapy in severe COVID-19; a case series. *Crit Care* 2020; 24:250.
407. Elharrar X, Trigui Y, Dois AM et al. Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure. *JAMA* 2020.
408. Reddy MP, Subramaniam A, Afroz A et al. Prone positioning of nonintubated patients with Coronavirus Disease 2019- A systematic review and meta-analysis. *Crit Care Med* 2021.
409. Xin Y, Martin K, Morais CC et al. Diminishing efficacy of prone positioning with late application in evolving lung injury. *Crit Care Med* 2021.
410. Haymet A, Bassi GL, Fraser JF. Airborne spread of SARS-CoV-2 while using high-flow nasal cannula oxygen therapy: myth or reality. *Intensive Care Med* 2020; 46:2248-51.
411. Francone M, Lafrate F, Masci GM et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. *European Radiology* 2020; 30:6808-17.
412. Kory P, Kanne JP. SARS-CoV-2 organizing pneumonia: "Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?". *BMJ Open Resp Res* 2020; 7:e000724.
413. Parry AH, Wani AH, Shah NN et al. Chest CT features of coronavirus disease-19 (COVID-19) pneumonia: which findings on initial CT can predict an adverse short-term outcome? *BJR Open* 2020; 2:20200016.
414. Zhang J, Meng G, Li W et al. Relationship of chest CT score with clinical characteristics of 108 patients hospitalized with COVID-19 in Wuhan, China. *Respiratory Research* 2020; 21:180.
415. Yang R, Li X, Liu H et al. Chest CT severity score: An imaging tool for assessing severe COVID-19. *Radiology: Cardiothoracic Imaging* 2020; 2:e2000047.
416. Li K, Wu J, Wu F et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. *Investigative Radiology* 2020; 55:1-5.
417. Pan F, Ye T, Sun P et al. Time course of lung changes at Chest CT during recovery from Coronavirus Disease 2019 (COVID-19). *Radiology* 2021; 295:715-21.
418. Ding X, Xu J, Zhou J et al. Chest CT findings of COVID-19 pneumonia by duration of symptoms. *European Journal of Radiology* 2020; 127:109009.
419. Bernheim A, Mei X, Huang M et al. Chest CT findings in Coronavirus disease 2019 (COVID-19): relationship to duration of infection. *Radiology* 2020; 295:685-91.
420. Ichikado K, Suga M, Muranka H et al. Prediction of prognosis for acute respiratory distress syndrome with thin-section CT: Validation in 44 cases. *Radiology* 2006; 238:321-29.
421. Ichikado K, Suga M, Muller NL et al. Acute interstitial pneumonia. Comparison of high-resolution computed tomography findings between survivors and nonsurvivors. *Am J Respir Crit Care Med* 2002; 165:1551-56.
422. Keith P, Day M, Perkins L et al. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. *Crit Care* 2020.
423. Keith P, Wells AH, Hodges J et al. The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: A single center experience. *Crit Care* 2020; 24:518.
424. Busund R, Koukline V, Utrobin U et al. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. *Intensive Care Med* 2002; 28:1434-39.
425. Morath C, Weigand MA, Zeier M et al. Plasma exchange in critically ill COVID-19 patients. *Crit Care* 2020; 24:481.
426. Khamis F, Al-Zakwani I, Al Hashmi S et al. Therapeutic plasma exchange in adults with severe COVID-19 infection. *Int J Infect Dis* 2020.
427. Fernandez J, Gratacos-Gines J, Olivias P et al. Plasma exchange: An effective rescue therapy in critically ill patients with Coronavirus Disease 2019 infection. *Crit Care Med* 2020.
428. Gucyetmez B, Atalan HK, Sertdemir I et al. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study. *Crit Care* 2020; 24:492.



429. Poor HD, Ventetuolo CE, Tolbert T et al. COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. medRxiv 2020.
430. Wang J, Najizadeh N, Moore EE et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated respiratory distress syndrome (ARDS): A case series. J Thromb Haemost 2020.
431. Patel M, Dominguez E, Sacher D et al. Etoposide as salvage therapy for cytokine storm due to Coronavirus Disease 2019. Chest 2021; 159:e7-e11.
432. Hamizi K, Aouidane S, Belaaloui G. Etoposide-based therapy for severe forms of COVID-19. Medical Hypotheses 2020; 142:109826.
433. Otsuka R, Seino KI. Macrophage activation syndrome and COVID-19. Inflammation Regeneration 2020; 40:19.
434. Opoka-Winiarska V, Grywalska E, Rolinski J. Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases? BMC Medicine 2020; 18:214.
435. Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Medicine 2017; 15:172.
436. Brisse E. Hemophagocytic lymphohistiocytosis (HLH): A heterogenous spectrum of cytokine-driven immune disorders. Cytokine Growth Factors Reviews 2015; 26:263-80.
437. Mehta R. Hemophagocytic lymphohistiocytosis (HLH) : a review of literature. Med Oncol 2013; 30:740.
438. Abou-Arab O, Huette P, Debouvries F et al. Inhaled nitric oxide for critically ill Covid-19 patients: a prospective study. Crit Care 2020; 24:645.
439. Bagate F, Tuffet S, Masi P et al. Rescue therapy with inhaled nitric oxide and almitrine in COVID-19 patients with severe acute respiratory distress syndrome. Ann Intensive Care 2020.
440. Caplan M, Goutay J, Bignon A et al. Almitrine infusion in severe acute respiratory syndrome coronavirus-2 induced acute respiratory distress syndrome: A single-center observational study. Crit Care Med 2020.
441. Payen D. Coronavirus disease 2019 acute respiratory failure: Almitrine drug resuscitation or resuscitating patients by almitrine? Crit Care Med 2020.
442. Henry MB, Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports. J Crit Care 2020; 58:27-28.
443. Abrams D, Lorusso R, Vincent JL et al. ECMO during the COVID-19 pandemic: when is it unjustified. Crit Care 2020; 24:507.
444. Supady A, Taccone FS, Lepper PM et al. Survival after extracorporeal membrane oxygenation in severe COVID-19 ARDS: results from an international multicenter registry. Crit Care Med 2021; 25:90.
445. Barbaro RP, MacLaren G, Boonstra PS et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020.
446. Cypel M, Keshavjee S. When to consider lung transplantation for COVID-19. Lancet Resp Med 2021; 8:944-46.
447. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med 2020.
448. Cerutti A, Chen K, Chorny A. Immunoglobulin responses at the mucosal interface. Annu Rev Immunol 2011; 29:273-93.
449. Jacobs JJ. Neutralizing antibodies mediate virus-immune pathology of COVID-19. Med Hypotheses 2020; 143:109884.
450. Caricchio R, Abbate A, Gordeev I et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19. A randomized clinical trial. JAMA 2021.
451. Seifirad S. Pirfenidone: A novel hypothetical treatment for COVID-19. Medical Hypotheses 2020; 144:11005.
452. Saba A, Vaidya PJ, Chavhan VB et al. Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2018; 35:85-90.
453. Spagnolo P, Balestro E, Aliberti S et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Resp Med 2020; 8:750-752.
454. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Resp Med 2020; 8:807-15.
455. Brouwer WP, Duran S, Kuijper M et al. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care 2019; 23:317.

456. Villa G, Romagnoli S, De Rosa S et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study. *Crit Care* 2020; 24:605.
457. Ahmad Q, DePerrior SE, Dodani S et al. Role of inflammatory biomarkers in the prediction of ICU admission and mortality in patients with COVID-19. *Medical Research Archives* 2020; 8:1-10.
458. Marik PE, Stephenson E. The ability of procalcitonin, lactate, white blood cell count and neutrophil-lymphocyte count ratio to predict blood stream infection. Analysis of a large database. *J Crit Care* 2020; 60:135-39.
459. Ichikado K, Muranaka H, Gushima Y et al. Fibroproliferative changes on high-resolution CT in the acute respiratory distress syndrome predict mortality and ventilator dependency: a prospective observational cohort study. *BMJ Open* 2012; 2:e000545.
460. Tan C, Huang Y, Shi F et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. *J Med Virol* 2020; 92:856-62.
461. Howell AP, Parrett JL, Malcom DR. Impact of high-dose intravenous vitamin C for treatment of sepsis on point-of-care blood glucose readings. *J Diabetes Sci Technol* 2019.
462. Stephenson E, Hooper MH, Marik PE. Vitamin C and Point of Care glucose measurements: A retrospective, Observational study [Abstract]. *Chest* 2018; 154 (suppl.):255a.
463. Hekimian G, Kerneis M, Zeitouni M et al. COVID-19 acute myocarditis and multisystem inflammatory syndrome in Adult Intensive and cardiac Care Units. *Chest* 2020.
464. Ma KL, Liu ZH, Cao CF et al. COVID-19 myocarditis and severity factors: An adult cohort study. *medRxiv* 2020.
465. Brosnahan SB, Bhatt A, Berger JS et al. COVID-19 pneumonia hospitalizations followed by re-presentation for presumed thrombotic event. *Chest* 2020.
466. Giannis D, allen SL, Tsang J et al. Post-discharge thromboembolic outcomes and mortality of hospitalized COVID-19 patients: The CORE-19 registry. *Blood* 2021.
467. Spyropoulos AC, Lipardi C, Xu J et al. Modified IMPROVE VTE Risk Score and elevated D-Dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. *TH Open* 2020; 4:e59-e65.
468. Kunutsor SK, Seidu S, Blom AW et al. Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence. *Eur J Epidemiol* 2017; 32:657-67.
469. Patterson BK, Francisco EB, Yogendra R et al. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. *bioRxiv* 2021.
470. Luvanda M, Posch W, Vosper J et al. Dexamethasone promotes *Aspergillus fumigatus* growth in macrophages by triggering M2 repolarization via targeting PKM2. *J Fungi* 2021; 7:70.
471. Reiter RJ, Sharma R, Ma Q et al. Plasticity of glucose metabolism in activated immune cells: advantages for melatonin inhibition of COVID-19 disease. *Melatonin Res* 2020; 3:362-79.
472. Ma WH, Zhang XG, Guo LL et al. Androgen receptor inhibition alleviated inflammation in experimental autoimmune myocarditis by increasing autophagy in macrophages. *European Review for Medical & Pharmacological Sciences* 2021; 25:3762-71.
473. Becerra-Diaz M, Strickland AB, Keselman A et al. Androgen and androgen receptor as enhancers of M2 macrophage polarization in allergic lung inflammation. *J Immunol* 2018; 201:2923-33.
474. Ma W, Zhang J, Guo L et al. Suppressed androgen receptor expression promotes M2 macrophage reprogramming through the STAT3/SOCS3 pathway. *EXCLI Journal* 2019; 18:21-29.
475. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. *JAMA* 2020.
476. Prescott HC, Girard TD. Recovery from Severe COVID-19. Leveraging the lessons of survival from sepsis. *JAMA* 2020.
477. Greenhalgh T, Knight M, A'Court C et al. Management of post-acute Covid-19 in primary care. *BMJ* 2020.
478. Chopra V, Flanders SA, O'Malley M. Sixty-day outcomes among patients hospitalized with COVID-19. *Ann Intern Med* 2020.
479. Mandal S, Barnett J, Brill SE et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalization for COVID-19. *Thorax* 2020.
480. Michelen M, Manoharan L, Elkheir N et al. Characterising long-term covid-19: a rapid living systematic review. *medRxiv* 2020.

481. Huang C, Huang L, Wang Y et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 2021.
482. Logue JK, Franko NM, McCulloch DJ et al. Sequelae in adults at 6 months after COVID-19 infection. *JAMA Network Open* 2021; 4:e210830.
483. Janiri D, Carfi A, Kotzalidis GD et al. Posttraumatic stress disorder in patients after severe COVID-19 infection. *JAMA Psychiatry* 2021.
484. Voruz P, Allali G, Benzakour L et al. Long COVID neuropsychological deficits after severe, moderate or mild infection. *medRxiv* 2021.
485. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature* 2021.
486. Yong SJ. Long-haul COVID-19: Putative pathophysiology, risk factors, and treatments. *medRxiv* 2020.
487. Taquet M, Geddes JR, Husain M et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry* 2021.
488. Afrin LB, Weinstock LB, Molderings GJ. COVID-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. *Int J Infect Dis* 2020.
489. Bryce C, Grimes Z, Pujadas E et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. *medRxiv* 2020.
490. Lu Y, Li X, Geng D et al. Cerebral micro-structural changes in COVID-19 patients - An MRI-based 3-month follow-up study. *EclinicalMedicine* 2020.
491. Franke C, Ferse C, Kreye J et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. *Brain, Behavior, and Immunity* 2021.
492. Sirous R, Taghvaei R, Hellinger JC et al. COVID-19-associated encephalopathy with fulminant cerebral vasoconstriction: CT and MRI findings. *Radiology Case Reports* 2020; 15:2208-12.
493. Magro CM, Mulvey JJ, Laurence J et al. Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019. *Human Pathology* 2020; 106:106-16.
494. Theoharides TT, Cholevas C, Polyzoidis K et al. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. *Biofactors* 2021; 47:232-41.
495. Riche F. Protracted immune disorders at one year after ICU discharge in patients with septic shock. *Crit Care* 2018; 22:42.
496. Andreaskos E, Papadaki M, Serhan CN. Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19. *Allergy* 2020.
497. COVID-19 rapid guideline: managing the long-term effects of COVID-19. [www.nice.org.uk/guidance/ng188](http://www.nice.org.uk/guidance/ng188) . 2020. National Institute for Health and Care Excellence. 4-26-2021.
498. Chen Y, Gu S, Chen Y et al. Six-month follow-up of gut microbiota richness in patients with COVID-19. *Gut* 2021.
499. Sanabria-Mazo JP, Montero-Marin J, Feliu-Soler A et al. Mindfulness-based program plus amygdala and insula retraining (MAIR) for the treatment of women with fibromyalgia: A pilot randomized controlled trial. *J Clin Med* 2020; 9:3246.
500. Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. *Biofactors* 2020; 46:306-8.
501. Bawazeer MA, Theoharides TC. IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF- $\kappa$ B, inhibited by methoxyluteolin. *Eur J Pharmacol* 2019; 865:172760.
502. Weng Z, Patel AB, Panagiotidou S et al. The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. *J Allergy Clin Immunol* 2015; 135:1044-52.
503. Patel AB, Theoharides TC. Methoxyluteolin inhibits neuropeptide-stimulated proinflammatory mediator release via mTOR activation from human mast cells. *J Pharmacol Exp Ther* 2017; 361:462-71.
504. Calis Z, Mogulkoc R, Baltaci AK. The roles of flavonols/flavonoids in neurodegeneration and neuroinflammation. *Mini Rev Med Chem* 2020; 20:1475-88.
505. Kurcicka L, Lauer SA, Laeyendecker O et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. *Ann Intern Med* 2020; 173:262-67.

506. Cheng HY, Jian SW, Liu DP et al. Contact tracing assessment of COVI-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. *JAMA Intern Med* 2020; 180:1156-63.
507. Zhao J, Yang Y, Huang H et al. Relationship between ABO blood group and the COVID-19 susceptibility. *medRxiv* 2020.
508. Banerjee A, Pasea L, Harris S et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. *Lancet* 2020; 395:1715-25.
509. Goren A, Vamo-Galvan S, Wambier CG et al. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain- A potential clue to the role of androgens in COVID-19 severity. *J Cosmetic Dermatol* 2020.
510. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395:497-506.
511. Guan W, Ni Z, Hu Y et al. Clinical characteristics of Coronavirus disease 2019 in China. *N Engl J Med* 2020.
512. von der Thusen J, van der Eerden M. Histopathology and genetic susceptibility in COVID-19 pneumonia. *Eur J Clin Invest* 2020.
513. Sweeney TE, Liesenfeld O, Wacker J et al. Validation of inflammopathic, adaptive, and coagulopathic sepsis endotypes in Coronavirus disease 2019. *Crit Care Med* 2020.
514. Tartof SY, Qian L, Hong V et al. Obesity and mortality among patients diagnosed with COVID-19: Results from an integrated health care organization. *Ann Intern Med* 2020.
515. Pujadas E, Chaudhry F, McBride R et al. SARS-CoV-2 viral load predicts COVID-19 mortality. *Lancet Resp Med* 2020.
516. Akbar AN, Gilroy DW. Aging immunity may exacerbate COVID-19. *Science* 2020; 369.
517. Zhang Q, Bastard P, Liu Z et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* 2020.
518. Li MY, Li L, Zhang Y et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. *Infectious Diseases of Poverty* 2020; 9:45.
519. Zhou Y, Fu B, Zheng X et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. *Natl Sci Rev* 2020; 7:998-1002.
520. Blanco-Melo D, Nilsson-Payant BE, Liu WC et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. *Cell* 2020; 181:1036-45.
521. Giamarellos-Bouboulis EJ, Netea MG, Rovina N et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. *Cell Host & Microbe* 2020.
522. McGonagle D, Sharif K, O'Regan A et al. The role of cytokines including interleukin-6 in COVID-19 induces pneumonia and macrophage activation syndrome-like disease. *Autoimmunity Reviews* 2020; 19:102537.
523. Zhou F, Yu T, Du R et al. Clinical course and risk factor for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020.
524. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Febratinib. *J Microbiol Immunol Infect* 2020.
525. Giamarellos-Bourboulis EJ, Netea MG, Rovina N et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. *medRxiv* 2020.
526. Mehta P, McAuley DF, Brown M et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; 395:1033-34.
527. Qin C, Zhou L, Hu Z et al. Dysregulation of the immune response in patients with COVID-19 in Wuhan, China. *Lancet Infect Dis* 2020.
528. Zhang C, Wu Z, Li JW et al. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. *Int J Antimicrob Agents* 2020.
529. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the "Cytokine Storm" in COVID-19. *J Infection* 2020.
530. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science* 2020.
531. Tay MZ, Poh CM, Renia L et al. The trinity of COVID-19: immunity, inflammation and intervention. *Nature Reviews* 2020; 20:363-74.
532. Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. *Intensive Care Med* 2020; 46:1105-8.

533. Teuwen LA, Geldhof V, Pasut A et al. COVID-19: the vasculature unleashed. *Nature Reviews* 2020.
534. Varga Z, Flammer AJ, Steiger P et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 2020.
535. Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary vascular endothelialitis, Thrombosis, and Angiogenesis in COVID-19. *N Engl J Med* 2020; 383:120-128.
536. Torrealba JR, Fisher S, Kanne JP et al. Pathology-radiology correlation of common and uncommon computed tomographic patterns of organizing pneumonia. *Human Pathology* 2018; 71:30-40.
537. Kanne JP, Little BP, Chung JH et al. Essentials for radiologists on COVID-19: an Update-Radiology Scientific Expert Panel. *Radiology* 2020.
538. Copin MC, Parmentier E, Duburcq T et al. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection [letter]. *Intensive Care Med* 2020.
539. Gattinoni L, Chiumello D, Caironi P et al. COVID-19 pneumonia: different respiratory treatment for different phenotypes? *Intensive Care Med* 2020; 46:1099-102.
540. Chiumello D, Cressoni M, Gattinoni L. Covid-19 does not lead to a "typical" Acute Respiratory Distress syndrome. *Lancet* 2020.
541. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? *Crit Care* 2020; 24:154.
542. Gattinoni L, Pesenti A. The concept of "baby lung". *Intensive Care Med* 2005; 31:776-84.
543. Patel AN, Desai SS, Grainger DW et al. Usefulness of ivermectin in COVID-19 illness. *medRxiv* 2020.
544. Jeronimo CM, Farias ME, Almeida FF et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): A randomised, double-blind, phase IIb, placebo-controlled trial. *Clin Infect Dis* 2020.
545. Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. *Am J Respir Crit Care Med* 2020.
546. Schurink B, Roos E, Radonic T et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. *Lancet Microbe* 2020.
547. Buijsters B, Yanginlar C, Maciej-Hulme ML et al. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. *EBioMedicine* 2020.
548. Kim SY, Jin W, Sood A et al. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. *Antiviral Res* 2020; 181:104873.
549. Clausen TM, Sandoval DR, Spliid CB et al. SARS-CoV-2 infection depends on cellular heparan sulphate and ACE2. *bioRxiv* 2020.
550. Kwon PS, Oh H, Kwon SJ et al. Sulphated polysaccharides effectively inhibit SARS-CoV-2 in vitro. *Cell Discovery* 2020; 6:50.
551. Huang X, Han S, Liu X et al. Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS-induced sepsis. *Exp Thera Med* 2020; 19:913-22.
552. Buijsters B, Yanginlar C, de Nooijer A et al. Increased plasma heparanase activity in COVID-19 patients. *medRxiv* 2020.
553. May JM, Qu ZC. Ascorbic acid prevents oxidant-induced increases in endothelial permeability. *Biofactors* 2011; 37:46-50.
554. Utoguchi N, Ikeda K, Saeki K et al. Ascorbic acid stimulates barrier function of cultured endothelial cell monolayer. *Journal of Cellular Physiology* 1995; 163:393-99.
555. Han M, Pendem S, Teh SL et al. Ascorbate protects endothelial barrier function during septic insult: Role of protein phosphatase type 2A. *Free Radic Biol Med* 2010; 48:128-35.
556. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. *Ann N Y Acad Sci* 2004; 1024:138-46.
557. Shodell M, Siegal FP. Corticosteroids depress INF-alpha-producing plasmacytoid dendritic cells in human blood. *J Allergy Clin Immunol* 2001; 108:446-48.
558. Thomas BJ, Porritt RA, Hertzog PJ et al. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. *Scientific Reports* 2014; 4:7176.
559. Singanayagam A, Glanville N, Girkin JL et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. *Nature Communications* 2018; 9:2229.
560. Salton F, Confalonieri P, Santus P et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. *medRxiv* 2020.
561. Braude AC, Rebuck AS. Prednisone and methylprednisolone disposition in the lung. *Lancet* 1983;995-97.
562. Sajid MS, Iqbal Z, Muhammad G et al. Effects of ivermectin on the cellular and humoral immune responses of rabbits. *Life Sci* 2007; 80:1966-70.

563. Blakley BR, Rousseaux CG. Effect of ivermectin on the immune response in mice. *Am J Vet Res* 1991; 52:593-95.